Pharmaceutical combination

a technology of combination and pharmaceuticals, applied in the field of pharmaceutical compositions, can solve the problems of too high systemic toxicity of antiviral compounds to allow skin or mucous membrane application, and achieve the effect of improving the appearance of a human and improving the pharmacological

Inactive Publication Date: 2006-09-05
MEDIVIR AB
View PDF18 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0030]It could be of advantage to utilize two or more antivirals or to combine the antiviral with an adjuvant or other additive in order to increase the effect on the herpesvirus to be treated, for instance in cases of resistance developed to a particular antiviral substance.
[0035]The carrier system should be stable and pharmaceutically and cosmetically acceptable. It should also enable incorporation of sufficient amounts of the active ingredients to give the proper penetration characteristics. In addition to conventional ingredients in creams, lotions, gels or ointments, compositions based on phospholipids, including sphingolipids can be advantageous.
[0044]In yet another aspect the pharmaceutical compositions of the present invention can also be used as a cosmetic composition to improve the appearance of a human suffering from an oral-facial HSV infection by application of an effective amount of said compositions to the lesions or rash.
[0045]The topical administration of the pharmaceutical compositions of the present invention have resulted in a significantly better pharmacological effect in the treatment of recurrent herpes infections than the administration of conventional topical compositions comprising an antiviral compound as the only active substance. This has been determined in biological tests by means of a new animal model described below.

Problems solved by technology

The systemic toxicity of the antiviral compounds is too high to allow for an application to the skin or mucous membrane.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical combination
  • Pharmaceutical combination
  • Pharmaceutical combination

Examples

Experimental program
Comparison scheme
Effect test

example 2

Cream of Budesonide 0.0125% and Foscarnet 1.5%

[0052]By simple mixing of Foscarnet Cream and budesonide cream (0.025%, Preferid®, Gist-Brocades, The Netherlands) a combination cream was obtained having the following composition:

[0053]

Amount (mg)Budesonide0.125Trisodium phosphonoformate hexahydrate15Sodium citrate0.6Citric adic0.3Sorbic acid0.3Cetostearyl alcohol30Paraffin liquid3Cetomacrogol 10006White soft paraffin15Arlatone (polyoxyethylene fatty acid ester)31Cetyl alcohol14Stearic acid14Mineral oil14Propylene glycol14Glycerol10.5Methyl p-hydroxybenzoate0.43Propyl p-hydroxybenzoate0.19Sodium hydroxide 2 M*Hydrochloric acid 2 M*Waterad 1000

example 4

Cream of Hydrocortisone 1%

[0056]

Amount (mg)Hydrocortisone10Methyl p-hydroxybenzoate2.0Propyl p-hydroxybenzoate0.5Glycerol0.03Ethanol5Isopropylmyristate50Amphisol10Paraffin30Paraffin, liquid40Macrogol stearate100Cetyl alcohol50Waterad 1000

[0057]This cream is commercially available as Hydrokortison kräm 1% ACO, Kabi Pharmacia AB, Sweden.

example 5

Cream of Foscarnet 2.4% and Hydrocortisone 1%

[0058]

Amount (% by weight)Trisodium phosphonoformate hexahydrate2.4Hydrocortisone1Phospholipids30Waterad 100

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
healing timeaaaaaaaaaa
weightaaaaaaaaaa
swellingaaaaaaaaaa
Login to view more

Abstract

The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.

Description

[0001]This application is a 371 of PCT / SE96 / 00124, filed Feb. 2, 1996.FIELD OF THE INVENTION[0002]The present invention relates to a pharmaceutical composition for topical administration suitable for the prophylaxis and treatment of herpesvirus infections. The pharmaceutical composition comprises a combination of an antiviral agent and an antiinflammatory agent and can preferably be used for the treatment of recurrent herpesvirus infections.BACKGROUND OF THE INVENTION[0003]Herpesvirus infections in humans can be caused by different human herpesviruses, the most common being herpes simplex virus and varicella-zoster virus. There are also many animal herpesviruses.[0004]Following a primary infection with herpes simplex virus or varicella-zoster virus, the virus establishes latency in the sensory nerve cells for the rest of the patient's life and can subsequently be reactivated repeatedly. Following a reactivation in the nerve cell, the virus is transported through the nerves to the sk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/56A61K9/10A61K9/00A61K31/52A61K31/57A61K31/58A61K31/66A61K31/675A61K31/70A61K45/06A61K47/00A61K47/02A61K47/06A61K47/10A61K47/12A61P31/12A61P31/22
CPCA61K9/0014A61K31/57A61K31/58A61K31/675A61K31/70A61K31/52A61K2300/00A61P27/02A61P31/12A61P31/22A61P43/00A61K31/56A61K31/66
Inventor HARMENBERG, JOHANKRISTOFFERSON, ANN HARRIET MARGARETA
Owner MEDIVIR AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap